Home/Pipeline/AL008

AL008

Oncology (Various Cancers)

PreclinicalResearch

Key Facts

Indication

Oncology (Various Cancers)

Phase

Preclinical

Status

Research

Company

Alector

About Alector

Alector is a clinical-stage biotech company with a mission to conquer neurodegenerative diseases by modulating the immune system. Its strategy is validated by major partnerships with GSK and AbbVie, and it is advancing a late-stage pipeline led by latozinemab in Phase 3 for frontotemporal dementia. The company's proprietary Alector Brain Carrier (ABC) platform aims to solve the critical challenge of blood-brain barrier delivery, positioning it at the forefront of a novel therapeutic paradigm.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Neurology Immunology

Other Oncology (Various Cancers) Drugs

Drug	Company	Phase	Status
Doxorubicin Hydrochloride Liposome Injection	ForDoz Pharma	Approved	Active
NP-101	Novatek Pharmaceuticals	Phase 1/2	Active
Biosimilar Bevacizumab	Strides Pharma	Development	Likely Active
AVT33	Alvotech	Early Phase	Active